WR 238605, Chloroquine, and their Combinations as Blood Schizonticides against a Chloroquine-Resistant Strain of Plasmodium vivax in Aotus Monkeys

Nicanor Obaldia III Promed Trading SA, Australian Army Malaria Research Unit, University of Sydney, Walter Reed Army Institute of Research, Panama City, Panama

Search for other papers by Nicanor Obaldia III in
Current site
Google Scholar
PubMed
Close
,
Richard N. Rossan Promed Trading SA, Australian Army Malaria Research Unit, University of Sydney, Walter Reed Army Institute of Research, Panama City, Panama

Search for other papers by Richard N. Rossan in
Current site
Google Scholar
PubMed
Close
,
Robert D. Cooper Promed Trading SA, Australian Army Malaria Research Unit, University of Sydney, Walter Reed Army Institute of Research, Panama City, Panama

Search for other papers by Robert D. Cooper in
Current site
Google Scholar
PubMed
Close
,
Dennis E. Kyle Promed Trading SA, Australian Army Malaria Research Unit, University of Sydney, Walter Reed Army Institute of Research, Panama City, Panama

Search for other papers by Dennis E. Kyle in
Current site
Google Scholar
PubMed
Close
,
Edwin O. Nuzum Promed Trading SA, Australian Army Malaria Research Unit, University of Sydney, Walter Reed Army Institute of Research, Panama City, Panama

Search for other papers by Edwin O. Nuzum in
Current site
Google Scholar
PubMed
Close
,
Karl H. Rieckmann Promed Trading SA, Australian Army Malaria Research Unit, University of Sydney, Walter Reed Army Institute of Research, Panama City, Panama

Search for other papers by Karl H. Rieckmann in
Current site
Google Scholar
PubMed
Close
, and
G. Dennis Shanks Promed Trading SA, Australian Army Malaria Research Unit, University of Sydney, Walter Reed Army Institute of Research, Panama City, Panama

Search for other papers by G. Dennis Shanks in
Current site
Google Scholar
PubMed
Close
Restricted access

The compound WR 238605 is a primaquine analog being developed by the U.S. Army as an antimalarial drug. Currently, there is no established treatment for Plasmodium vivax parasitemias that are not cured by chloroquine. This study tested WR 238605, chloroquine, and their combinations against a chloroquine-resistant strain of P. vivax (AMRU 1) in Aotus monkeys. A total dose of 3 mg/kg of WR 238605 given at a dosage of 1 mg/kg/day for three days cleared patent parasites in all eight monkeys but recrudescence of parasitemia occurred 15–25 days after initiation of treatment. A total dose of 9 mg/kg of WR 238605 over a three-day period cured all three monkeys of their infections. A total dose of 30 mg/kg of chloroquine did not clear patent infections in three monkeys, whereas a total dose of 60 mg/kg generally (two of three) cleared patent parasitemia but did not cure. Whereas total doses of 30 mg/kg of chloroquine or 3 mg/kg of WR 238605 given alone failed to cure, both drugs given in combination at these dosages cured two of three infections. These results indicate that WR 238605 may be an alternative treatment for chloroquine-resistant vivax malaria.

Author Notes

Save